Bristol Myers Squibb Acquires Orum’s ORM-6151
On November 6, Bristol Myers Squibb (BMS) announced that it entered into an agreement to acquire Orum Therapeutics’ GSPT1 platform. Under this transaction, BMS will pay an upfront payment of $100 million, and Orum Therapeutics is eligible to receive milestone payments for a total deal value of $180 million. Orum Therapeutics’ GSPT1 platform uses unique Dual-Precision Targeted Protein Degradation (TPD) approach to build novel targeted protein degraders combined with the precise tumor cell delivery mechanisms of antibodies. This generates innovative, first-in-class, tumor-selective TPDs for the treatment of cancer. BMS is a global biopharmaceutical company whose... Read More »
JLL Report: 2023 Life Sciences Industry and Real Estate Perspective
Recently, JLL released a report titled, “2023 Life Sciences Industry and Real Estate Perspective: Assessing the future landscape for biopharma, medtech and biomanufacturing” that explores the real estate landscape of technology sectors. According to data captured in the LevinPro HC database, JLL has advised on 24 transactions in 2023. Of those, there were 19 medical office buildings, two inpatient behavioral health hospitals, one ambulatory surgery center and one acute care facility. In total, the 50 facilities consist of more than 4.2 million square feet. The report was broken down into multiple sections that looked at various elements of the market. Below, we’ve summarized each... Read More »
Aileron Therapeutics Acquires Lung Therapeutics
Aileron Therapeutics, Inc. has announced its acquisition of Lung Therapeutics. Financial terms of the deal were not disclosed. Lung Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for underserved, life-threatening lung conditions. The Lung Therapeutics pipeline features leading programs LTI-01 and LTI-03, two candidates that indicate a novel way to treat lung diseases. Aileron Therapeutics is a chemoprotection oncology company focused on the clinical development of its lead product candidate, ALRN-6924, to protect cancer patients against chemotherapy-induced toxicities. Following the acquisition, Aileron entered into a definitive... Read More »
Roche Acquires Telavant for $7.1 Billion
Roche Holding AG announced on October 23 that it will acquire Telavant Holdings from its majority owner, Roivant Sciences. Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. Telavant is a biotechnology company that produces drugs to treat inflammatory and fibrotic diseases. It is in the process of developing a new therapy for patients with Crohn’s disease. Telavant was jointly formed by Roivant and Pfizer, Inc. in 2022 to develop and commercialize RVT-3101, a monthly subcutaneously administered anti-TL1A antibody, in the United States and Japan. Roivant currently owns 75% of the issued and... Read More »
Eli Lilly Acquires POINT Biopharma Global For $1.4 Billion
Eli Lilly and Company announced on October 2 that it acquired POINT Biopharma Global, Inc. for approximately $1.4 billion. Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash payable at closing. The price represents a premium of approximately 87% to POINT’s closing stock price on Oct. 2, 2023, the last trading day before the announcement of the transaction was made, and 68% to the 30-day volume-weighted average price. POINT Biopharma Global is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
